Aquestive Therapeutics, Inc. (AQST) vs Phathom Pharmaceuticals, Inc. (PHAT)
A side-by-side comparison of Aquestive Therapeutics, Inc. and Phathom Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AQST
Aquestive Therapeutics, Inc.
$4.61HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
PHAT
Phathom Pharmaceuticals, Inc.
$6.78HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — AQST vs PHAT
growth of $100 · dividends reinvested · last 7yAQST +45.1% (+5.5%/yr)PHAT -72.8% (-17.0%/yr)AQST compounded faster over this window
Log scale — wide-divergence pair
AQST PHAT
AQST vs PHAT: by the numbers
- •AQST is the larger company ($578M vs $549M market cap).
- •Both run net losses; PHAT's is the smaller (-41.34% vs -144.63% net margin).
Metrics side by side
Valuation
| Metric | AQST | PHAT |
|---|---|---|
| P/S ratio | 10.69 | 2.29 |
Profitability
| Metric | AQST | PHAT |
|---|---|---|
| Gross margin | 67.04% | 82.92% |
| Operating margin | -156.36% | -91.36% |
| Net margin | -144.63% | -41.34% |
| ROIC | -45.62% | -23.45% |
Growth (annualized)
| Metric | AQST | PHAT |
|---|---|---|
| Revenue CAGR (5Y) | -0.58% | N/A |
| Total return CAGR (5Y) | 2.24% | -26.93% |
Frequently asked
- How have AQST and PHAT total returns compared?
- Over the past 5 years, AQST delivered 2.24% and PHAT delivered -26.93% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.